Taiho Oncology, Inc.
Kathy Calarco has extensive work experience in the pharmaceutical and healthcare industry. Kathy is currently the Senior Vice President of Quality at Taiho Oncology, Inc. since January 2023. Before that, they served as the Vice President of Quality at the same company from March 2020 to January 2023. Prior to Taiho Oncology, Inc., Kathy worked at Johnson & Johnson as the Consumer Sector Head of BioResearch Quality and Compliance from September 2018 to March 2020. Kathy also held various positions at Janssen, Pharmaceutical Companies of Johnson and Johnson from January 2006 to September 2018, including Senior Director of Compliance, Scientific Systems, and Laboratory Operations. Kathy began their career at Merck as a Laboratory Compliance Manager from January 1995 to December 2005.
Kathy Calarco obtained their Bachelor's degree in Biology, General from Saint Joseph's University from 1989 to 1993.
This person is not in any offices
Taiho Oncology, Inc.
2 followers
The mission of Taiho Oncology, Inc. is to improve the lives of patients with cancer, their families and their caregivers. The company specializes in the development of orally administered anti-cancer agents and markets these medicines for a range of tumor types in the U.S. Taiho Oncology’s growing pipeline of selectively targeted anti-cancer agents is led by a world-class clinical development organization. Taiho Oncology is a subsidiary of Taiho Pharmaceutical Co., Ltd. which is part of Otsuka Holdings Co., Ltd. Taiho Oncology is headquartered in Princeton, New Jersey and oversees its parent company’s European and Canadian operations, which are located in Zug, Switzerland and Oakville, Ontario, Canada. For more information, visit www.taihooncology.com